Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 14th International Conference and Exhibition on Nanomedicine and Pharmaceutical Nanotechnology Amsterdam, Netherlands.

Day :

Conference Series NanoPharma 2018 International Conference Keynote Speaker Edouard Alphandéry photo
Biography:

Edouard Alphandéry has completed his PhD from Oxford University and Postdoctoral studies from Trinity College and the University of Washington. He is an Assistant Professor at the UPMC, France. He has published more than 30 papers in reputed journals and submitted 10 patent families.

 

 

Abstract:

 

In this study, biologically synthesized iron oxide nanoparticles, called magnetosomes, are made fully biocompatible by removing potentially toxic organic bacterial residues such as endotoxins at magnetosome mineral core surface and by coating such surface with poly-L-lysine, leading to magnetosomes-poly-L-lysine (M-PLL). M-PLL antitumor efficacy is compared with that of chemically synthesized iron oxide nanoparticles (IONPs) currently used for magnetic hyperthermia. M-PLL and IONPs are tested for the treatment of glioblastoma, a dreadful cancer, in which intratumor nanoparticle administration is relevant, using a mouse allograft model of murine glioma (GL-261 cell line). A magnetic hyperthermia treatment protocol is proposed, in which 25µg in iron of iron oxide nanoparticles per mm3 of tumor are administered and exposed to 11 to 15 magnetic sessions during which an alternating magnetic field of 198kHz and 11 to 31mT was applied for 30 minutes to attempt reaching temperatures of 43-46°C. M-PLL are characterized by a larger specific absorption rate (SAR of 40W/gFe compared with 26W/gFe for IONPs as measured during the first magnetic session), a lower strength of the applied magnetic field required for reaching a target temperature of 43-46°C (11 to 27mT compared with 22 to 31mT for IONPs), a lower number of mice re-administered (four compared to six for IONPs) and a longer residence time within tumors (four days compared to one day for IONPs). Despite of a less homogenous that dispersion M-PLL are less homogenously dispersed in the tumor compared to IONPs, M-PLL lead to higher antitumor efficacy with full tumor disappearances achieved in 50% of mice compared with 20% for IONPs.

 

  • Nanomedicine and Biomedical Applications| Design of Nanodrugs| Nanomedicine and Nanotechnology| Synthesis of Nanoparticles for Drug Delivery| Novel Drug Delivery Systems
Location: Meeting place 2
Speaker

Chair

Sergey Suchkov

Sechenov University, Russia

Session Introduction

Aiman Abu Ammar

Azrieli College of Engineering Jerusalem, Israel

Title: Controlled release of steroids utilizing drug-eluting endotracheal tube
Biography:

Aiman Abu Ammar is a Faculty Member in the Department of Pharmaceutical Engineering at Azrieli College of Engineering, Israel. He has completed his Pharmacy studies, MSc in Medicinal Chemistry, and PhD in Pharmaceutical Sciences at The Hebrew University of Jerusalem. He has joined Nanoengineering Group at Technion, as Senior Scientist. He is a licensed Pharmacist and has research experience in nano-drug delivery systems for the treatment of solid tumors and performs multi-disciplinary research with a focus on development of localized drug delivery systems using nanotechnology. He is a Co-inventor of 1 patent in this field.

 

Abstract:

Intubation-related morbidity is a common complication that usually involves the larynx and trachea, leading to local irritation, inflammation, and edema. Such complication is secondary to airway mucosal damage due to the use of an endo-tracheal tube (ETT), which produces local pressure and a pressure-like ulcer. The common clinical approach to manage airway mucosal damage is systemic administration of steroids hours to days prior to extubation, however, such treatment is inadequate, and some patients will need to undergo tracheostomy. Herein, steroid-eluting ETT for local treatment was developed for the purpose of improving drug efficiency and avoiding systemic steroid related side effects. Electrospinning technique was utilized to coat ETTs and produce a microscale layer of poly (lactic-co-glycolic acid) (PLGA) nanofibers loaded with Mometasone Furoate (MF). The novel delivery system was fully characterized, by means of drug loading, morphology, and mechanical stability of fiber mats. Moreover, in vitro release study demonstrated controlled release of MF over 14 days. The MF-coated ETTs exhibited superior therapeutic response compared to blank ETTs using an in vivo rat model, in terms of reduced laryngeal mucosal thickness and submucosal laryngeal edema. Taken together, steroid-loaded ETT is a novel approach allows for local drug delivery in a controlled manner, for improved treatment of intubation-related morbidity.

 

Biography:

Sergey Suchkov has graduated from Astrakhan State Medical University and awarded with MD, then in 1985, completed his PhD at the I.M. Sechenov Moscow Medical Academy and in 2001, completed his Doctorship Degree at the Nat. Inst. of Immunology, Russia. From 1987 through 1989, he was a senior Researcher, Koltzov Inst. of Developmental Biology. From 1989 through 1995, he was a Head of the Lab of Clinical Immunology, Helmholtz Eye Research Institute in Moscow. From 1995 through 2004, a Chair of the Dept for Clinical Immunology, Moscow Clinical Research Institute. He has been trained at: NIH; Wills Eye Hospital, PA, USA; Univ. of Florida in Gainesville; UCSF, S-F, CA, USA; Johns Hopkins University, Baltimore, MD, USA. He was an Exe Secretary-in-Chief of the Editorial Board, Biomedical Science, an international journal published jointly by the USSR Academy of Sciences and the Royal Society of Chemistry, UK. At present, he is the Chair, Dept. for Personalized and Translational Medicine, I.M. Sechenov First Moscow State Medical University. He is a Member of the: New York Academy of Sciences, USA; American Chemical Society (ACS), USA; American Heart Association (AHA), USA; EPMA (European Association for Predictive, Preventive and Personalized Medicine), Brussels, EU; ARVO (American Association for Research in Vision and Ophthalmology); ISER (International Society for Eye Research) and PMC (Personalized Medicine Coalition), Washington, USA.

 

Abstract:

Catalytic Abs (catAbs) is multivalent immunoglobulin’s (Igs) with a capacity to hydrolyze the antigenic (Ag) substrate. In this sense, proteolytic Abs (Ab-proteases) represents Abs to provide proteolytic effects. Abs against myelin basic protein/MBP with proteolytic activity exhibiting sequence-specific cleavage of MBP is of great value to monitor demyelination whilst in MS. The activity of Ab-proteases was first registered at the subclinical stages 1-2 years prior to the clinical illness. And the activity of the Ab-proteases revealed significant correlation with scales of demyelination and the disability of the patients as well. So, the activity of Ab-proteases and its dynamics tested would confirm a high subclinical and predictive (translational) value of the tools as applicable for personalized monitoring protocols. Of tremendous value are Ab-proteases directly affecting remodeling of tissues with multilevel architectonics (for instance, myelin). By changing sequence specificity, one may reach reduction of a density of the negative proteolytic effects within the myelin sheath and thus minimizing scales of demyelination. Ab-proteases can be programmed and re-programmed to suit the needs of the body metabolism or could be designed for the development of new catalysts with no natural counterparts. Further studies are needed to secure artificial or edited Ab-proteases as translational tools of the newest generation to diagnose, to monitor, to control and to treat and rehabilitate MS patients at clinical stages and to prevent the disorder at subclinical stages in persons-at-risks to secure the efficacy of regenerative manipulations.

 

Image

 

 

Recent Publications:

 

  1. Ponomarenko N A, Durova O M, Vorobiev I I, Aleksandrova E S, Telegin G B, Chamborant O G, Sidorik L L, Suchkov S V, Alekberova Z S, Gnuchev N V and Gabibov A G (2002) Catalytic antibodies in clinical and experimental pathology: human and mouse models. Journal of Immunological Methods. 269 (1-2): 197-211.

 

  1. Ponomarenko N A, Durova O M, Vorobiev I I, Belogurov A A, Telegin G B, Suchkov S V and A G Gabibov (2005) Catalytic activity of autoantibodies toward myelin basic protein correlates with the scores on the multiple sclerosis expanded disability status scale. Immunol. Lett. 103 (1): 45-50.
  2. Gabibov A G, Ponomarenko N A, Tretyak E B, Paltsev M A, Suchkov S V (2006) Catalytic autoantibodies in clinical autoimmunity and modern medicine. Autoimmunity Reviews. 5 (5): 324-330.

 

  1. Gabibov A A, Paltsev M A, Suchkov S V (2011) Antibody-associated proteolysis in surveillance of autoimmune demyelination: clinical and preclinical issues Future Neurology. 6 (3): 303-305.

 

  1. D Kostyushev, I Tsarev, D Gnatenko, M Paltsev, S Suchkov (2011) Myelin-associated serological targets as applicable to diagnostic tools to be used at the preclinical and transient stages of multiple sclerosis progression. Open J Immunology. 1 (3): 80-86.

 

Biography:

Bita Rasoulian has completed her graduation from Maziar University, Royan, Mazandaran in the field of Biomedical Engineering and Biomaterials. She is a Research Assistant of Nanomedicine under Supervision of Dr. Shima Tavakol at Cellular and Molecular Research Center, Iran University of Medical Science. However, she is interested in the investigation of nanomaterials and their influence and interaction with biological systems especially nervous and bone. Meanwhile, she has expertise in in-vitro and in-vivo studies, as well. Her major researches have been on spinal cord injuries and craniofacial injuries, modeling and treating them with various specified nanomedicines in which she has gained exclusive results.

 

Abstract:

To date, spinal cord injury (SCI) has remained an incurable disaster. The use of self-assembling peptide nanofiber containing bioactive motifs such as bone marrow homing peptide (-BMHP1) as an injectable scaffold in spinal cord regeneration has been suggested and investigated earlier. Although, in all the investigation, the effect of biological motifs have been investigated but the influence of self-assembling core of peptide nanofibers in tissue engineering has been neglected. In the present investigation for the first time, the influence of two major core of self-assembling peptide nanofibers attached to the famous neurogenic biological motif of BMHP1 was assessed. BE2M17 one of the reference cell line (human neuroblastoma cell line) in neurological investigation was choose and cells were treated with the peptide nanofibers and cell behavior investigated. Then cells were differentiated for four days and neural genes were assessed by real time PCR. To investigate the spinal cord recovery potential of nanofibers, they were implanted into a chronic model of SCI in rat. Results showed that the core of KSL-B induced higher cell viability and LDH release while the core of RADA-B exhibits higher acidic environment and induced more ROS, NO production and higher amount of PI positive cells (Dead cells) with higher percentage of Sub-G1 in cell cycle characterized by flowcytometery. However, these results were in good agreement with BAX/BCL2 ratio indicated higher BAX/BCL2 ratio for cells treated by RADA-B. Interestingly, the RADA-B induced higher gene expression of nNOS in agreement with NO production. Results showed that although RADA-B induced higher gene expression of Integrin 5 as a cell membrane signaling receptor but KSL-B over-expressed higher gene of focal adhesion kinase 2 as a downstream of integrin and resulted in higher gene expression of Nestin, MAP2, TH, GFAP and GDNF while the over-expression of NF and GABA was higher in RADA-B. Interestingly, RADA-B induced over-expression of GABA while, KSL induced over-expression of TH. The BBB score of spinal cord injury model in rat disclosed that KSL-B induced higher motor recovery in rats. In conclusion, it might be said that based on the targeted tissue the core of self-assembling peptide nanofiber must be choose. In a bone with acidic friendly environment the RADA core would be better (data not shown) while in the neural tissue, KSL with less inducible acidic environment would be preferred.

 

Biography:

Edouard Alphandéry has completed his PhD from Oxford University and Postdoctoral studies from Trinity College and the University of Washington. He is an Assistant Professor at the UPMC, France. He has published more than 30 papers in reputed journals and submitted 10 patent families.

 

Abstract:

Biologics magnetics nanoparticles, magnetosomes, attract attention because of their magnetic characteristics and potential applications. The aim of present study was to develop and characterize a novel magnetosomes extracted from magnetotactic bacteria, purified to produce apyrogen magnetosome minerals, and then coated with chitosan, neridronate, or polyethyleneimine, to yield stable magnetosomes designated as M-Chi, M-Neri, and M-PEI, respectively. The biocompatibility of nanoparticles was evaluated with mouse fibroblast cells (3T3), Mouse glioblastoma cells (GL-261) and Rat glioblastoma cells (RG-2). Also, we tested these nanoparticles for magnetic hyperthermia treatment of tumor in vitro with GL-261 exposed an alternating magnetic field, heating properties, efficiency and internalization was then evaluated. Nanoparticles coated with chitosan, polyethyleneimine and neridronate are apyrogen, biocompatible and stable in aqueous suspension. The presence of a thin coating in M-Chi and M-PEI favors an arrangement in chains of the magnetosomes, similar to that observed in magnetosomes directly extracted from magnetotactic bacteria, while the thick matrix embedding M-Neri leads to structures with an average of 3.5µm2 per magnetosome mineral. In the presence of GL-261 cells and upon application of an alternating magnetic field, M-PEI and M-Chi lead to the highest specific absorption rates of 120-125W/gFe. Furthermore, while M-Chi lead to rather low rates of cellular internalization, M-PEI strongly associate to cells, a property modulated by application of an alternating magnetic field. Coating of purified magnetosome minerals can therefore be chosen to control the interactions of nanoparticles with cells, organization of the minerals, as well as heating properties and cytotoxicity, which are important parameters to be considered in the design of a magnetic hyperthermia treatment of tumor.

 

Biography:

Zumra Peksaglam has completed her BS in Chemical Engineering from Gazi University (Ankara, Turkey) in 2012, and MS in Chemical Engineering from University of Southern California (USC) in 2016. Currently, she is studying photo-triggered surfactant systems for control of protein unfolding and gene delivery at Dr. Charles Ted Lee’s laboratory as a 3rd year PhD student at USC. She is also 2nd year student of Health, Technology and Engineering graduate certificate program which is an interdisciplinary program between Viterbi Engineering and Keck School of Medicine.

 

Abstract:

Light-sensitive nanoparticles for siRNA and Paclitaxel co-delivery: They are catanionic vesicles that are formed spontaneously upon the interaction of an azobenzene-based cationic surfactant and a conventional anionic surfactant. As a result of the photo-responsive property of azobenzene moieties, the light-sensitive microstructure can be switched with light illumination from vesicles to micelles, lamellar structures, or free surfactant monomers. The usage of nanoparticles for chemotherapeutic drugs has a potential to increase cancer treatment efficiency. Additionally, a prospective therapeutic genetic material, siRNA, can be used to deactivate targeted mRNAs that cause inhibition of disease-associated protein production. Thus, the unique photo-assisted transition of vesicles to free monomers of light-sensitive nanoparticles were used to encapsulate both siRNA and a chemotherapeutic drug, Paclitaxel, to cancer cells and, then control the release of them by UV light exposure. In this work, the effect of hydrophobic tail of cationic surfactants on particle size, charge and surface characteristics are measured by small-angle neutron scattering (SANS), dynamic light scattering (DLS), zeta potential meter and cryo-transmission electron microscopy (cryo-TEM) to create an ideal delivery vector. The encapsulation efficiency and cellular uptake capability of Bcl-2 siRNA and Paclitaxel co-delivery through MDA-MB-231 human breast cancer cells are explored as 8:1 ratio of vesicle:PTX and 10:1 (w:w) N:P ratio (vesicle/siRNA) with 45% of cellular uptake. Therefore, azobenzene-based catanionic vesicles are used as a co-delivery nanovehicle to develop siRNA-based therapeutics with a hydrophobic anticancer drug. It is expected to improve tumor therapeutic efficacy by the usage of the unique photo-assisted delivery agent.

 

Biography:

Bita Rasoulian has completed her graduation from Maziar University, Royan, Mazandaran in the field of Biomedical Engineering and Biomaterials. She is a Research Assistant of Nanomedicine under Supervision of Dr. Shima Tavakol at Cellular and Molecular Research Center, Iran University of Medical Science. However, she is interested in the investigation of nanomaterials and their influence and interaction with biological systems especially nervous and bone. Meanwhile, she has expertise in in-vitro and in-vivo studies, as well. Her major researches have been on spinal cord injuries and craniofacial injuries, modeling and treating them with various specified nanomedicines in which she has gained exclusive results.

 

Abstract:

Todays, nano-pharmaceutics as a major branch of nanomedicine has developed and there are some nanoformulations in market with less side effect and high efficacy and bioavailability in patients. Although, the basic investigation in this field has critical importance to design of safer nanoformulation but there are no reports that investigate in parallel the effect of ethanol concentrations as a major co-surfactant in nanoemulsions and some other type of nanoformulations along with the particle size. So, for the first time, NPs with equal and different particle size at same and different concentrations of ethanol were prepared and their influence on cell behavior and inflammatory and apoptosis genes were investigated. NPs with no ethanol were nominated 3.10 and at the ethanol concentrations of 3 and 5% were nominated 3.10.3 and 3.10.5 and if the temperature was applied they were nominated 3.10T, 3.10.3T and 3.10.5T. The particle size of 3.10 and 3.10.3 were same and had a mid diameter of 56.8nm, however temperature applying resulted in larger particle size in both group, 78.9 and 77.7nm, respectively. Increase of ethanol concentration from 3 to 5 % decreased particle size in non-temperature and temperature formulations to 47.9 and 70.7nm, respectively. Thermodynamic stability showed no sign of biphasic and physical appearance in the formulations and TLC disclosed that all the nano-formulations had equal Rf of 0.14. Based on the mentioned results, it might be said that temperature, surfactant, co-surfactant and the preparation method not damage to the curcumin as a drug substitute. In conclusion, it might be said that the particle with average diameter of 70-78nm were more up-taken by cells than smaller ones and induce more integrin gene expression and larger ones exhibit less damaging effects on cell membrane and induces less intracellular ROS production and afterwards iNOS gene expression and inflammatory gene of NF-KB. However, smaller nanoformulation around 49-56nm exhibited higher cell viability by the MTT assay, BCL2 gene expression and less NO production. Based on our findings, it seems that cell viability FAK2 gene expression have more direct effect than integrin gene over-expression and cell up take on cell migration and the 3.10, 3.10T and 3.10.5T induce higher cell migration than others, respectively that they were in good agreement with the FAK2 gene over-expression.

 

  • Nano Pharmaceuticals| Nanobiotechnology| Graphene Medicine| Personalized Nanomedicine| Regulatory Aspects Towards Approval of Nanomedicine and Pharmaceutical
Location: Meeting Place 2

Chair

Hugo Albrecht

University of South Australia, Australia

Session Introduction

Hugo Albrecht

University of South Australia, Australia

Title: Targeting prostate cancer cells with hybrid elastin-like polypeptide/liposome nanoparticles
Biography:

Hugo Albrecht is a Senior Lecturer at the University of South Australia and a Member of the Centre for Drug Discovery and Development within the division of Health Sciences. Prior to his appointment to the University of South Australia, he has held various positions in academic and commercial settings in Switzerland and the US, where he gained profound experience in preclinical drug discovery.

 

Abstract:

For a long time, prostate cancer has been considered chemo-refractory. Only during the last 10-15 years, have good results been achieved in clinic trials with taxane derivatives such as docetaxel (DTX) and cabazitaxel. However, disabling toxicities including fatigue and neuropathy limit optimal dosage and therefore only modest, life prolonging effects have been achieved for prostate cancer patients. Future treatment outcomes might potentially be improved through targeted delivery of chemotherapeutic compounds into cancer cells while reducing the exposure of healthy tissue. Prostate cancer cells frequently overexpress the gastrin releasing peptide receptor (GRPR) and various strategies have been applied in preclinical settings to target this receptor for the specific delivery of anti-cancer compounds. Recently, it has been proposed that elastin-like polypeptide (ELP)-based, self-assembling micelles with tethered gastrin-releasing peptide (GRP) on the surface might be useful for active targeting of prostate cancer cells. Although poorly soluble chemotherapeutics such as docetaxel have been loaded into the hydrophobic cores of ELP micelles, only limited drug retention times have been achieved. We report the generation of hybrid ELP/liposome nanoparticles which self-assemble rapidly in response to temperature change, encapsulating docetaxel at high concentrations with slow release. The GRP ligand was displayed on the surface and specifically bound to GRP receptor expressing PC-3 cells as demonstrated by flow cytometry. This novel type of drug nanocarrier was successfully used to reduce cell viability of prostate cancer cells in vitro through the specific delivery of docetaxel.

 

Image

 

 

Figure: Specific targeting of prostate cancer cells with hybrid ELP/liposome nanoparticles.

 

Recent Publications:

 

1.                  Zhang W, Garg S, Eldi P, et al (2016) Targeting prostate cancer cells with genetically engineered polypeptide-based micelles displaying gastrin-releasing peptide. Int J Pharm. 513 (1): 270-279.

 

2.                  Shi P, Aluri S, Lin YA, et al (2013) Elastin-based protein polymer nanoparticles carrying drug at both corona and core suppress tumor growth in vivo. J Control Release. 171 (3): 330-338.

 

3.                  Na K, Lee SA, Jung SH, Hyun J and Shin BC (2012) Elastin-like polypeptide modified liposomes for enhancing cellular uptake into tumor cells. Colloids Surf B Biointerfaces. 91: 130-136.

 

4.                  Pereira S, Egbu R, Jannati G and Al-Jamal WT (2016) Docetaxel-loaded liposomes: The effect of lipid composition and purification on drug encapsulation and in vitro toxicity. Int J Pharm. 514 (1): 150-159.

 

5.                  Naguib YW, Rodriguez BL, Li X, Hursting SD, Williams RO 3rd and Cui Z (2014) Solid lipid nanoparticle formulations of docetaxel prepared with high melting point triglycerides: in vitro and in vivo evaluation. Mol Pharm. 11 (4): 1239-1249.

 

Biography:

Bita Rasoulian has completed her graduated from Maziar University, Royan, Mazandaran in the field of Biomedical Engineering, Biomaterials in Bachelor degree on 2017. She is a Research Assistant of Nanomedicine under Supervision of Dr. Shima Tavakol at Cellular and Molecular Research Center, Iran University of Medical Science. However, she is interested in the investigation of nanomaterials and their influence and interaction with biological systems especially nervous and bone. Meanwhile, she has expertise in in-vitro and in-vivo studies, as well. Her major researches has been on spinal cord injuries and craniofacial injuries, modeling and treating them with various specified nanomedicines in which she has gained exclusive results.

 

Abstract:

Bone is a real nanocompsite of nanofibers and nano ceramics and approximately 600,000 suffers from craniofacial deficits in US. RADA as a core of self-assembling peptides exhibits an acidic pH while the pH of KSL is higher than RADA. The acidic pH of RADA usually is an obstacle in tissue engineering but by regards to the acidophilic nature of bone, it was investigated for the first time. In the present investigation, for the first time the BMHP motif was bound to the RADA and KSL as a core of self-assembling peptide nanofiber and was evaluated its cell viability, ROS, NO and LDH release on MG-63 cell line as a cell line of bone osteosarcoma and then its effects was evaluated as a gene expression of apoptotic and integrins. Then, they were implanted in a critical size bone defect in rats for two month and densitometry of bone defects were analyzed and compared. Results showed that KSL core due to higher cell viability, BCL2 gene over-expression and less intracellular ROS production was more effective than RADA ones in bone regeneration. However, KSL showed higher cell membrane damage and BAX gene over-expression than RADA. These data were in good agreement with X-ray radiographic data that disclosed higher bone density in KSL nanofiber than RADA. Based on the presented data since KSL induced higher nerve regeneration (not shown) and bone regeneration it is a good candidate for spine repair that its biodegradation will improve motor neuron recovery, as well.

 

Biography:

Manal M Kamel is a Professor of Immunology at Theodor Bilharz Research Institute (TBRI), Giza, Egypt. She has graduated from the Faculty of Medicine, Cairo University. Her Postgraduate studies were in Immunology and Clinical Pathology. She has a great experience in the fields of antigen preparation, nanotechnology, monoclonal production, CB MSCs transplantation. She has supervised (9) MSc and PhD thesis, two of them in the field of nanotechnology with stem cells and monoclonal antibodies. She has published more than 23 papers in reputed journals and has been serving as Member in the selected referee lists of: The International Journal of Immunological Studies-Cell proliferation.

 

Abstract:

MSCs were generated and propagated from umbilical cord blood (UCB) and characterized by immunophenotyping using flow cytometry. Hepatogenic differentiation was induced on 2D and 3D (nanofiber scaffold) culture system. Gene expression analysis was done by real-time PCR. Human albumin and α-1 antitrypsin (AAT) in cell culture supernatants was performed by ELISA. Differentiated cells were administered intravenously into a murine model of CCL4 induced liver cirrhosis. Animal models were divided into three groups, a) Pathological control, b) CCL4 treated with hepatogenic differentiated MSCs on 2D vessels, c) CCL4 treated with hepatogenic differentiated MSCs cultured on nanofiber scaffold (3D). Liver pathology was examined 12 weeks after treatment with cells. The hepatogenic differentiated MSCs stained positively with more abundant and mature cells with hexagonal shape and central nuclei forming large sheets in 3D than 2D at day 28. By scanning electron microscopy hepatogenic differentiated cells showed strong adherence and penetration onto the surfaces of the nanofibrous scaffolds. (AAT) secretion and indocyanine green uptake on day 21 was significantly increased in 3D rather than 2D. In experimental model, MSC-3D scaffold group stained with Sirius red and Masson Trichrome exhibited maximal restoration of liver architecture with absent septal fibrosis. In contrast, hepatic fibrosis decreased to a lesser extent in MSC-2D group. Liver function tests revealed marked improvement of ALT, AST in 3D treated group. Both 3D and 2D culture system are effective in functional hepatogenic differentiation and serve as a suitable vehicle in liver tissue engineering. In vivo hepatogenic differentiation is more effective on 3D nanofibrous scaffold, with better functional recovery.

 

Biography:

Delivery of therapeutic nanoparticles (NPs) by stem and progenitor cells can overcome the limitations of NP carriers and can create opportunities for stem cell transplantation. In this respect, we studied the interaction between engineered NPs and ex vivo derived hematopoietic progenitor cells (HPC). CD34-positive HPC were derived from human cord blood and were exposed to fluorescent carboxylate polystyrene NPs of 40, 100 and 200nm size, and to 50nm SiO2 NPs. NP uptake kinetics were assessed by measuring fluorescence intensity at short time intervals using flow cytometry. HPCs demonstrated a rapid (within 1 hour), but transient loading behavior which was retained upon changing the size and composition of the NPs. Using confocal microscopy fluorescent NPs were observed to appear mainly at the outer boundary of the cells, while only few were located in the intracellular compartment. These findings contrast with reported observations of steadily increasing NP internalization in other cell types, such as phagocytic cells or cell lines, and suggest that CD34+ progenitor cells handle NPs by using different mechanisms. Further research will be conducted to investigate the processes underlying the interactions between the NPs and the cellular membrane.

 

Abstract:

In 2014 I obtained a Master’s degree in biomedical sciences with a specialization in bio-electronics and nanotechnology at the university of Hasselt. In 2015 a started a joint-PhD between Hasselt University and VITO. VITO is a technological research institute working for the Flemish government.

 

Artur Jedrzak

NanoBioMedical Centre, Adam Mickiewicz University in Poznan, Poland

Title: Dendrimers PAMAM grafted on smart Fe3O4@PDA composite and its application in cancer treatment.
Biography:

Artur JÄ™drzak received the M.Sc., Eng. degree in Organic Chemistry in 2016 at Poznan University of Technology. Since 2016 he is a Ph.D. student of Chemical Technologyat Poznan University of Technology and  he is also a member of NanoBioMedical Centre in Poznan. His research interests are biosensors, enzymatic and catalytic systems and synthesis of hybrid/composite materials for nanomedicine.

 

Abstract:

Current development of nanotechnology influences on a synthesis of novel and  more efficent drug carriers for nanomedicine, especially in cancer treatment. The application of specific nanomaterials like dendrimers PAMAM is currently a prominent topic in cancer therapy due to their internal cavities, water solubility, and modifiable surface functionality rhat render them as interesting carrier for drug delivery .

The other most commonly used material in cancer treatment are magnetic nanoparticles of iron oxide. In particular, the magnetite (Fe3O4)  nanoparticles has drawn a lot of attention since they are biocompatible, nontoxic, size/shape-tunable and they havehigh surface/volume  ratio and allow easy separation from  mixtures by application of an external magnetic field. Morover, that magnetite can be used as contrasting agents in nuclear magnetic resonance imaging (MRI), thus they arean ideal component to construct advanced teranostatic-nanotools. Further, polydopamine (PDA) coated magnetite exhibit  high photothermal properties and they are recently extensively investigated in cancer treatemnt.

Here we present, the PAMAM dendrimers grafted to the PDA a coated magnetic nanoparticles as atractive theranostic for dual chemo- and phothermal theraphy. Obtained Fe3O4@PDA@PAMAM nanocarriers were characterized by means of TEM, zeta potential, FT-IR, XPS,  magnetic meseremnsts  and MRI. Further the results regarding drug loading and  it release profile will be discussed as well as their application in vitro in  combined chemo- and phothermal theraphy of  liver cancer.